Novel miniaturized coupled drugs, peptide/nanoantibody

Conjustar Biologics is focused on the development of innovative miniaturized conjugated drugs, specifically peptide-drug conjugates (PDCs) and nanoantibody-drug conjugates (NDCs), aimed at treating solid tumors. The company has established a robust technology platform that supports the research and development of these novel therapies, which are designed to target specific cancer markers, thereby enhancing treatment efficacy while minimizing side effects. Their commitment to advancing cancer treatment is evident in their ongoing clinical trials and the recent approvals for investigational new drugs (INDs) by regulatory authorities in both China and the United States.

The company’s pipeline includes several promising candidates, such as SC-101 and SC-102, which have received IND approvals for the treatment of advanced malignant solid tumors. These drugs are designed to target specific proteins associated with cancer cells, showcasing Conjustar's strategic focus on precision medicine in oncology. By leveraging their advanced technology platform and strategic partnerships, Conjustar aims to contribute significantly to the global fight against cancer, emphasizing their dedication to innovation and patient care in the biopharmaceutical industry.

United States

Tianjin Conjustar Biotechnology Co., Ltd. is a researcher and developer of peptide-drug conjugate intended for oncology treatments. The company was established in early 2022 and is located in Tianjin Airport Free Trade Zone. It was founded by Fosun Health Capital and focuses on cooperative development and independent research.

Conjustar

Company Details